Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.48 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.47 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.47 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3201690 | 1.00 | CNR2 (0.48) | CNR2VCAM1CA12CA9SMN1; SMN2 | |
| SCHEMBL3193958 | 1.00 | CNR2 (0.48) | CNR2VCAM1CA12CA9SMN1; SMN2 | |
| SCHEMBL3196045 | 1.00 | CNR2 (0.48) | CNR2VCAM1CA12CA9SMN1; SMN2 | |
| SCHEMBL3193841 | 1.00 | CNR2 (0.48) | CNR2VCAM1CA12CA9SMN1; SMN2 | |
| SCHEMBL3198478 | 1.00 | CNR2 (0.48) | CNR2VCAM1CA12CA9SMN1; SMN2 | |
| SCHEMBL3200608 | 0.98 | VCAM1 (0.49) | CNR2VCAM1CA12CA9SMN1; SMN2 | |
| SCHEMBL2677005 | 0.93 | SMN1; SMN2 (0.50) | VCAM1CA12CA9SMN1; SMN2CA2 | |
| SCHEMBL11418681 | 0.87 | KDM4E (0.51) | CNR2VCAM1CA12CA9SMN1; SMN2 | |
| SCHEMBL483162 | 0.86 | CA9 (0.57) | VCAM1CA12CA9SMN1; SMN2CA2 | |
| SCHEMBL9769423 | 0.85 | VCAM1 (0.43) | CNR2VCAM1SMN1; SMN2SERPINE1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678907-B2 | Halogenation of rylen-carboximides with elementary halogen in a two-phase mixture comprising an organic solvent and water, wherein formed halogen hydroxide is continuously removable from the organic solvent | BASF AKTIENGESSELLSCHAFT (DE) | 2010-03-16 | — | — | US | disclosed |
| EP-1802622-B1 | HALOGENATION OF RYLEN-CARBOXIMIDES WITH ELEMENTARY HALOGEN IN A TWO-PHASE MIXTURE COMPRISING AN ORGANIC SOLVENT AND WATER, WHEREIN FORMED HALOGEN HYDROCIDE IS CONTINUOUSLY REMOVABLE FROM THE ORGANIC SOLVENT | BASF SE (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-20080058526-A1 | Halogenation of Rylen-Carboximides with Elementary Halogene in a Two-Phase Mixture Comprising an Organic Solvent and Water, Wherein Formed Halogene Hydrocide is Continously Removable from the Organic Solvent | BASF AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | US | disclosed |
| EP-1802622-A1 | HALOGENATION OF RYLEN-CARBOXIMIDES WITH ELEMENTARY HALOGEN IN A TWO-PHASE MIXTURE COMPRISING AN ORGANIC SOLVENT AND WATER, WHEREIN FORMED HALOGEN HYDROCIDE IS CONTINUOUSLY REMOVABLE FROM THE ORGANIC SOLVENT | BASF AKTIENGESELLSCHAFT (DE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006037539-A1 | HALOGENATION OF RYLEN-CARBOXIMIDES WITH ELEMENTARY HALOGEN IN A TWO-PHASE MIXTURE COMPRISING AN ORGANIC SOLVENT AND WATER, WHEREIN FORMED HALOGEN HYDROCIDE IS CONTINUOUSLY REMOVABLE FROM THE ORGANIC SOLVENT | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058526-A1 | Halogenation of Rylen-Carboximides with Elementary Halogene in a Two-Phase Mixture Comprising an Organic Solvent and Water, Wherein Formed Halogene Hydrocide is Continously Removable from the Organic Solvent | CYP8B1, HACL2, CTRB2 | CNR2 137/4885VCAM1 3506/4885CA12 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.